Of all the research areas covered on this site, the longevity and mitochondrial peptide category may be the most scientifically compelling. These compounds target the fundamental biology of ageing itself — mitochondrial dysfunction, telomere shortening, cellular senescence, and the steady decline of NAD+ that underpins so many age-related conditions. Rather than addressing symptoms, this class of peptides is being studied for its potential to intervene at the cellular machinery level.

The standout compound in this category is SS-31 (Elamipretide), a mitochondria-targeting peptide that concentrates at the inner mitochondrial membrane and protects cardiolipin — a lipid essential for the electron transport chain. SS-31 has received FDA Breakthrough Therapy designation for heart failure with preserved ejection fraction, making it one of the most clinically advanced peptides in this entire catalogue. Alongside it, MOTS-C is a mitochondrial-derived peptide that activates AMPK and promotes mitochondrial biogenesis, with research interest spanning metabolic regulation, exercise performance, and longevity pathways.

Epithalon (Epitalon) is a tetrapeptide derived from the pineal gland that has been studied for its ability to stimulate telomerase activity — the enzyme responsible for maintaining telomere length. Alongside it, FOXO4-DRI represents a newer class of senolytic peptides designed to selectively induce apoptosis in senescent cells, which accumulate with age and drive chronic inflammation. NAD+ Injectable addresses the well-documented age-related decline in NAD+, a coenzyme central to sirtuin activation, DNA repair, and cellular energy metabolism.

This is one of the most rapidly evolving areas of peptide research globally. New findings emerge regularly, and the compounds in this collection sit at the intersection of geroscience, metabolic medicine, and cellular biology. All products are supplied for research purposes only. Researchers new to this area are encouraged to read our introduction to peptides and review our safety information before beginning any protocol.